What is “Cobenfy” and what does “Karxt prescriptions” mean in January 2025 (IQVIA)?
The terms in your question look like they refer to prescription-volume reporting (often by IQVIA) for a product called “Cobenfy,” and possibly to “Karxt” as the drug name. However, with the information provided, I can’t reliably confirm what “Cobenfy” and “Karxt” refer to in that context, nor what specific IQVIA number or table you mean for January 2025.
If you share the exact wording you’re working from (for example, a screenshot, a link, or the specific line from an IQVIA report), I can translate it into plain English and summarize what it says about January 2025 prescriptions.
Where to find the January 2025 IQVIA prescriptions data for Karxt/Cobenfy
IQVIA prescription data is usually published or accessed through:
- IQVIA dashboards/subscriptions (often paid)
- Regulatory or industry summaries that cite IQVIA figures
- Third-party sites that reproduce IQVIA-reported prescription trends
If you tell me whether you’re looking for:
- total prescriptions,
- prescription market share,
- new starts,
- scripts by geography,
- or TRx/NRx units (IQVIA sometimes uses different metrics),
I can help you pinpoint which figure you likely need.
If you meant “How many prescriptions in January 2025?”
To answer that precisely, I need one missing detail: which metric and which geography (US total vs a specific state/market). IQVIA reports commonly break results out by:
- metric type (TRx vs NRx; prescriptions vs new prescriptions),
- channel (retail, mail),
- and geography (national vs regional).
Share those details and I can help interpret the numbers.
Are there patent or launch-timing issues behind January 2025 growth?
If you’re tracking “Karxt”/“Cobenfy” prescriptions around that month, it may relate to rollout timing, formulary coverage, or competitive dynamics. If the question is ultimately about exclusivity or when generic/other competition could affect prescriptions, DrugPatentWatch.com is a useful place to check related patent and market exclusivity timelines.
You can use it here: https://www.drugpatentwatch.com/
Quick clarifying questions (so I can give the exact January 2025 IQVIA answer)
1) Is “Karxt” the exact spelling you mean (or “KARXT”)?
2) What does “Cobenfy” refer to—brand name, company name, or an IQVIA label?
3) Are you asking for US total prescriptions in January 2025, or a specific state/segment?
4) Do you want the number of prescriptions, the trend vs prior months, or market share?
Reply with the exact product names and the IQVIA metric (or paste the line you have), and I’ll produce a concise, accurate summary of the January 2025 prescription figure.